- Home
- SMID vs NGEN Comparison
SMID vs NGEN Comparison
Compare SMID & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SMID | NGEN |
|---|---|---|
| Founded | 1960 | 2017 |
| Country | United States | Canada |
| Employees | N/A | 9 |
| Industry | Building Materials | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.3M | 175.1M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | SMID | NGEN |
|---|---|---|
| Price | $30.83 | $1.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 5.9K | ★ 1.2M |
| Earning Date | 04-14-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.76 | N/A |
| EPS | ★ 2.36 | N/A |
| Revenue | ★ $93,446,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.06 | ★ N/A |
| Revenue Growth | ★ 19.03 | N/A |
| 52 Week Low | $25.60 | $1.87 |
| 52 Week High | $43.62 | $5.93 |
Technical Indicators
Market Signals| Indicator | SMID | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 47.93 | 25.23 |
| Support Level | $26.74 | N/A |
| Resistance Level | $36.74 | $4.52 |
| Average True Range (ATR) | 1.52 | 0.15 |
| MACD | 0.03 | -0.08 |
| Stochastic Oscillator | 56.61 | 1.05 |
Price Performance
Historical ComparisonAbout SMID Smith-Midland Corporation
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.